BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 7693430)

  • 1. Current status of dopamine agonists in Parkinson's disease management.
    Montastruc JL; Rascol O; Senard JM
    Drugs; 1993 Sep; 46(3):384-393. PubMed ID: 7693430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine agonists and Parkinson's disease.
    Burton K; Calne DB
    Clin Neurol Neurosurg; 1984; 86(3):172-7. PubMed ID: 6091965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacology of dopamine agonists in Parkinson's disease.
    Lange KW
    Drugs Aging; 1998 Nov; 13(5):381-9. PubMed ID: 9829165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D; Hanssens Y; Northway MG
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopaminergic agonists in the treatment of Parkinson's disease.
    Goetz CG; Diederich NJ
    Neurol Clin; 1992 May; 10(2):527-40. PubMed ID: 1350052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine receptor stimulating agonists in the treatment of Parkinson's disease.
    Agid Y; Barroche G; Bonnet AM; Javoy-Agid F; Kato G; Lhermitte F; Pollak P; Signoret JL
    Biomedicine; 1979 Jun; 30(2):67-71. PubMed ID: 383169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.
    Nyholm D
    Clin Pharmacokinet; 2006; 45(2):109-36. PubMed ID: 16485914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine agonists in Parkinson's disease.
    Calne DB; Burton K; Beckman J; Martin WR
    Can J Neurol Sci; 1984 Feb; 11(1 Suppl):221-4. PubMed ID: 6231979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Parkinson's disease should begin with a dopamine agonist.
    Montastruc JL; Rascol O; Senard JM
    Mov Disord; 1999 Sep; 14(5):725-30. PubMed ID: 10495032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms.
    Bravi D; Mouradian MM; Roberts JW; Davis TL; Sohn YH; Chase TN
    Ann Neurol; 1994 Jul; 36(1):27-31. PubMed ID: 8024257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DA agonists -- ergot derivatives: lisuride: management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S74-8. PubMed ID: 12211144
    [No Abstract]   [Full Text] [Related]  

  • 12. DA agonists -- ergot derivatives: bromocriptine: management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S53-67. PubMed ID: 12211141
    [No Abstract]   [Full Text] [Related]  

  • 13. [Apomorphine in off state--clinical experience].
    RudziƄska M; Szczudlik A
    Neurol Neurochir Pol; 2007; 41(2 Suppl 1):S40-8. PubMed ID: 17941458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in the clinical pharmacology of Parkinson's disease.
    Montastruc JL
    Therapie; 1991; 46(4):293-303. PubMed ID: 1683024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ergot and non-ergot dopamine agonists and heart failure in patients with Parkinson's disease.
    Montastruc F; Moulis F; Araujo M; Chebane L; Rascol O; Montastruc JL
    Eur J Clin Pharmacol; 2017 Jan; 73(1):99-103. PubMed ID: 27796464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine agonists in the treatment of Parkinson s disease past, present and future.
    Sit SY
    Curr Pharm Des; 2000 Aug; 6(12):1211-48. PubMed ID: 10903391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
    Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
    Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiation of dopamine agonists and their role in the treatment of Parkinson's disease.
    Calne DB
    J Neural Transm Suppl; 1999; 56():185-92. PubMed ID: 10370912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the clinical pharmacology of (-)NPA and levodopa in Parkinson's disease.
    Mouradian MM; Heuser IJ; Baronti F; Giuffra M; Conant K; Davis TL; Chase TN
    J Neurol Neurosurg Psychiatry; 1991 May; 54(5):401-5. PubMed ID: 1865201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DA agonists -- ergot derivatives: pergolide: management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S79-82. PubMed ID: 12211145
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.